General Information of Drug (ID: DMAESIY)

Drug Name
ANX005 Drug Info
Indication
Disease Entry ICD 11 Status REF
Neurodegenerative disorder 8A20-8A23 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMAESIY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cinryze DMVIKJZ Hereditary angioedema 4A00.14 Approved [2]
Sutimlimab DMY7WH1 Cold type autoimmune haemolytic anemia 3A20.1 Approved [3]
SAR445088 DMQV3IM Chronic inflammatory demyelinating polyneuropathy 8C01.3 Phase 2 [4]
TS01 DMNTVUK Stroke 8B20 Phase 1 [5]
SHP616 DMO0CA8 Neuromyelitis optica 8A43 Phase 1 [6]
TNT009 DMSKF29 Bullous pemphigoid EB41.0 Phase 1 [6]
Fucose DMAHMSV N. A. N. A. Investigative [7]
PMID16460935C28 DM8BKI4 Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C1s component (C1S) TT7LRQH C1S_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
3 Antibodies to watch in 2020. MAbs. Jan-Dec 2020;12(1):1703531.
4 First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor. Clin Transl Sci. 2023 Apr;16(4):673-685.
5 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8 A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2200-4.